Greenland Mines Ltd (NASDAQ: GRML) is a pre-revenue biotechnology company that is developing gene therapy and biosimilar biologic product candidates. The company has generated no operating revenues as of its 10-K filed April 1, 2026, and funds operations through outside financing. Its historical financial statements reflect those of the accounting acquirer, ANEW Medical, Inc. (a Wyoming corporation), following a business combination completed June 21, 2024. The company acquired its licensed platforms and patents and has conducted preclinical research and development in collaboration with Universitat Autònoma de Barcelona (UAB) and RLS. It changed its name and stock symbol to GRML on NASDAQ on March 12, 2026, following a merger with Greenland Mines Corp. dated March 4, 2026. As of March 30, 2026, the company had 121,238,660 shares of common stock outstanding. CEO is Joseph A. Sinkule and CFO is Jeffrey LeBlanc, as of April 1, 2026.

Revenue model

No operating revenues have been generated as of the filing date (10-K, filed April 1, 2026). The company relies on outside financing, including equity issuances, warrant conversions, and convertible notes, to fund operations.

Products and services

Gene therapy product candidates and biosimilar biologic product candidates, in preclinical and early development stages. The company uses AAV and lentiviral vectors and lipid nanoparticles for gene therapy delivery. No products have received regulatory approval as of the filing date.

Customers and end markets

No commercial customers as of the filing date. Target end markets include pharmaceutical and biologic therapeutics, subject to government and third-party payor reimbursement environments in the United States and the EU.

Value-chain role

Early-stage drug developer. The company licenses platforms and patents, conducts preclinical research primarily through its collaboration with UAB, and plans clinical testing and eventual commercialization. Manufacturing and research activities involve hazardous materials subject to regulatory oversight.

Geographic exposure

Operations referenced across the United States and EU regulatory and reimbursement environments. Collaboration with Universitat Autònoma de Barcelona (UAB) indicates international research activity. No specific revenue by geography, as no revenues have been generated.

Source: SEC 10-K, filed 2026-04-01

Industry: Biological Products, (No Diagnostic Substances) Peers: California First Leasing Corp FlexShopper, Inc. Future Fintech Group Inc HA Sustainable Infrastructure Capital Inc Sundance Strategies Inc SUI Group Holdings Ltd SHF Holdings Inc Standard Premium Finance Holdings Inc